Leaflet OXALIPLATIN KABI 5mg / ml concentrate for solution for infusion


Indicated for: colorectal cancer

Route of administration: infusion

Substance: oxaliplatin (antineoplastic agent)

ATC: L01XA03 (Antineoplastic and immunomodulating agents | Other antineoplastic agents | Platinum compounds)

Oxaliplatin is a chemotherapy agent used in the treatment of advanced or metastatic colorectal cancer. It works by binding to the DNA of tumor cells, inhibiting their replication and causing cell death.

The medication is administered intravenously, as directed by a doctor, usually in combination with other chemotherapy drugs. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as peripheral neuropathy, nausea, or diarrhea. It is important to inform the doctor of any unusual symptoms.

Common side effects include peripheral neuropathy, nausea, and diarrhea. In rare cases, severe reactions such as myelosuppression or allergic reactions may occur. Patients should be informed of these risks before use.

General data about OXALIPLATIN KABI 5mg / ml

  • Substance: oxaliplatin
  • Date of last drug list: 01-05-2026
  • Commercial code: W65013001
  • Concentration: 5mg / ml
  • Pharmaceutical form: concentrate for solution for infusion
  • Quantity: 1
  • Product type: generic
  • Price: 64.67 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: FRESENIUS KABI ONCOLOGY PLC. - MAREA BRITANIE
  • Holder: FRESENIUS KABI ROMANIA S.R.L. - ROMANIA
  • Number: 10109/2017/01
  • Shelf life: 2 years after packing for marketing; dupa diluare 24 h la 2-8°C and 6 h la 15-25°C

Compensation lists for OXALIPLATIN KABI 5mg / ml Fresenius

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

64.67 RON

64.67 RON

0.00 RON